Mongolia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 4.28 (3.88 - 4.70) | 2019 | Modelled | IHME |
| 4.44 (4.02 - 4.86) | 2018 | Modelled | IHME |
| 4.55 (4.08 - 5.03) | 2017 | Modelled | IHME |
| 4.6 (4.12 - 5.03) | 2016 | Modelled | IHME |
| 4.65 (4.14 - 5.15) | 2015 | Modelled | IHME |
| 4.75 (4.22 - 5.24) | 2014 | Modelled | IHME |
| 4.9 (4.34 - 5.38) | 2013 | Modelled | IHME |
| 5.07 (4.47 - 5.56) | 2012 | Modelled | IHME |
| 5.22 (4.60 - 5.75) | 2011 | Modelled | IHME |
| 5.34 (4.67 - 5.89) | 2010 | Modelled | IHME |
| 5.42 (4.75 - 5.99) | 2009 | Modelled | IHME |
| 5.48 (4.81 - 6.05) | 2008 | Modelled | IHME |
| 5.54 (4.85 - 6.11) | 2007 | Modelled | IHME |
| 5.59 (4.88 - 6.20) | 2006 | Modelled | IHME |
| 5.65 (4.88 - 6.31) | 2005 | Modelled | IHME |
| 5.72 (4.95 - 6.40) | 2004 | Modelled | IHME |
| 5.78 (4.98 - 6.49) | 2003 | Modelled | IHME |
| 5.85 (4.98 - 6.57) | 2002 | Modelled | IHME |
| 5.92 (5 - 6.69) | 2001 | Modelled | IHME |
| 6.01 (5.01 - 6.83) | 2000 | Modelled | IHME |
| 6.13 (5.11 - 6.95) | 1999 | Modelled | IHME |
| 6.3 (5.28 - 7.14) | 1998 | Modelled | IHME |
| 6.48 (5.48 - 7.32) | 1997 | Modelled | IHME |
| 6.63 (5.65 - 7.51) | 1996 | Modelled | IHME |
| 6.73 (5.70 - 7.68) | 1995 | Modelled | IHME |
| 6.78 (5.71 - 7.73) | 1994 | Modelled | IHME |
| 6.83 (5.72 - 7.81) | 1993 | Modelled | IHME |
| 6.87 (5.72 - 7.90) | 1992 | Modelled | IHME |
| 6.9 (5.71 - 7.99) | 1991 | Modelled | IHME |
| 6.91 (5.70 - 8.12) | 1990 | Modelled | IHME |
| 10.8 (8.80 - 13.31) | 2015 | Modelled | WHO |
| 4.1 (3.10 - 4.80) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.29 (0.20 - 0.36) | 2019 | Modelled | IHME |
| 0.31 (0.21 - 0.41) | 2018 | Modelled | IHME |
| 0.33 (0.22 - 0.43) | 2017 | Modelled | IHME |
| 0.32 (0.22 - 0.42) | 2016 | Modelled | IHME |
| 0.31 (0.21 - 0.40) | 2015 | Modelled | IHME |
| 0.33 (0.22 - 0.42) | 2014 | Modelled | IHME |
| 0.35 (0.24 - 0.46) | 2013 | Modelled | IHME |
| 0.4 (0.27 - 0.51) | 2012 | Modelled | IHME |
| 0.44 (0.29 - 0.58) | 2011 | Modelled | IHME |
| 0.49 (0.32 - 0.64) | 2010 | Modelled | IHME |
| 0.56 (0.36 - 0.73) | 2009 | Modelled | IHME |
| 0.64 (0.43 - 0.84) | 2008 | Modelled | IHME |
| 0.73 (0.49 - 0.95) | 2007 | Modelled | IHME |
| 0.8 (0.53 - 1.03) | 2006 | Modelled | IHME |
| 0.82 (0.55 - 1.07) | 2005 | Modelled | IHME |
| 0.82 (0.54 - 1.07) | 2004 | Modelled | IHME |
| 0.81 (0.52 - 1.07) | 2003 | Modelled | IHME |
| 0.79 (0.50 - 1.06) | 2002 | Modelled | IHME |
| 0.78 (0.48 - 1.06) | 2001 | Modelled | IHME |
| 0.78 (0.47 - 1.06) | 2000 | Modelled | IHME |
| 0.79 (0.49 - 1.08) | 1999 | Modelled | IHME |
| 0.84 (0.53 - 1.12) | 1998 | Modelled | IHME |
| 0.9 (0.59 - 1.19) | 1997 | Modelled | IHME |
| 0.99 (0.66 - 1.29) | 1996 | Modelled | IHME |
| 1.09 (0.75 - 1.41) | 1995 | Modelled | IHME |
| 1.29 (0.90 - 1.66) | 1994 | Modelled | IHME |
| 1.65 (1.13 - 2.14) | 1993 | Modelled | IHME |
| 2.12 (1.42 - 2.80) | 1992 | Modelled | IHME |
| 2.69 (1.78 - 3.60) | 1991 | Modelled | IHME |
| 3.3 (2.18 - 4.48) | 1990 | Modelled | IHME |
| 1.72 (1.14 - 2.57) | 2015 | Modelled | WHO |
| 0.5 (0.40 - 0.70) | 2009 | Survey/reported | WHO WPRO, Woodring J et al, 2017 |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 148,908 (122,697 - 174,814) | 1990 | Modelled | IHME |
| 151,393 (125,232 - 175,361) | 1991 | Modelled | IHME |
| 153,322 (127,492 - 176,219) | 1992 | Modelled | IHME |
| 154,715 (129,534 - 176,726) | 1993 | Modelled | IHME |
| 155,680 (130,998 - 177,450) | 1994 | Modelled | IHME |
| 156,324 (132,363 - 178,509) | 1995 | Modelled | IHME |
| 155,852 (132,825 - 176,369) | 1996 | Modelled | IHME |
| 153,876 (130,154 - 173,816) | 1997 | Modelled | IHME |
| 151,235 (126,788 - 171,420) | 1998 | Modelled | IHME |
| 148,710 (123,797 - 168,464) | 1999 | Modelled | IHME |
| 147,203 (122,714 - 167,206) | 2000 | Modelled | IHME |
| 146,601 (123,643 - 165,447) | 2001 | Modelled | IHME |
| 146,322 (124,667 - 164,400) | 2002 | Modelled | IHME |
| 146,288 (125,961 - 164,251) | 2003 | Modelled | IHME |
| 146,470 (126,686 - 163,971) | 2004 | Modelled | IHME |
| 146,787 (126,822 - 163,832) | 2005 | Modelled | IHME |
| 147,363 (128,487 - 163,415) | 2006 | Modelled | IHME |
| 148,250 (129,792 - 163,701) | 2007 | Modelled | IHME |
| 149,313 (131,019 - 164,762) | 2008 | Modelled | IHME |
| 150,343 (131,775 - 166,211) | 2009 | Modelled | IHME |
| 151,141 (132,299 - 166,854) | 2010 | Modelled | IHME |
| 150,896 (132,927 - 166,063) | 2011 | Modelled | IHME |
| 149,482 (132,020 - 163,975) | 2012 | Modelled | IHME |
| 147,659 (130,730 - 162,300) | 2013 | Modelled | IHME |
| 146,270 (129,864 - 161,378) | 2014 | Modelled | IHME |
| 146,212 (130,031 - 161,961) | 2015 | Modelled | IHME |
| 147,679 (132,234 - 161,446) | 2016 | Modelled | IHME |
| 148,920 (133,519 - 164,690) | 2017 | Modelled | IHME |
| 148,043 (133,909 - 161,766) | 2018 | Modelled | IHME |
| 145,106 (131,459 - 159,109) | 2019 | Modelled | IHME |
| 126,000 (95,000 - 146,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 29.1 (20.30 - 39.90) | 2019 | Modelled | IHME |
| 29.1 (20.50 - 40) | 2018 | Modelled | IHME |
| 29 (20.60 - 39.80) | 2017 | Modelled | IHME |
| 28.6 (20.40 - 38.90) | 2016 | Modelled | IHME |
| 28 (20.20 - 38.10) | 2015 | Modelled | IHME |
| 27.9 (20.20 - 37.30) | 2014 | Modelled | IHME |
| 27.9 (20.60 - 36.90) | 2013 | Modelled | IHME |
| 28 (20.90 - 36.40) | 2012 | Modelled | IHME |
| 28.1 (21 - 36.20) | 2011 | Modelled | IHME |
| 28 (21 - 36.10) | 2010 | Modelled | IHME |
| 27.5 (20.60 - 35.20) | 2009 | Modelled | IHME |
| 26.8 (20.30 - 34.30) | 2008 | Modelled | IHME |
| 26.3 (19.90 - 33.40) | 2007 | Modelled | IHME |
| 25.8 (19.70 - 32.90) | 2006 | Modelled | IHME |
| 25.2 (19.20 - 32.40) | 2005 | Modelled | IHME |
| 24.8 (19 - 31.60) | 2004 | Modelled | IHME |
| 24.7 (18.90 - 31.70) | 2003 | Modelled | IHME |
| 24.6 (19 - 31.50) | 2002 | Modelled | IHME |
| 24.5 (18.90 - 31.40) | 2001 | Modelled | IHME |
| 24 (18.60 - 30.40) | 2000 | Modelled | IHME |
| 23.7 (18.40 - 29.70) | 1999 | Modelled | IHME |
| 23.8 (18.60 - 29.70) | 1998 | Modelled | IHME |
| 24 (18.90 - 30.10) | 1997 | Modelled | IHME |
| 24.3 (19.30 - 30.40) | 1996 | Modelled | IHME |
| 24.2 (19.20 - 30.40) | 1995 | Modelled | IHME |
| 24.1 (19 - 30) | 1994 | Modelled | IHME |
| 24.2 (19.10 - 30.10) | 1993 | Modelled | IHME |
| 24 (19 - 29.80) | 1992 | Modelled | IHME |
| 24 (19 - 29.90) | 1991 | Modelled | IHME |
| 23.9 (18.70 - 30) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 987 (689 - 1,351) | 2019 | Modelled | IHME |
| 970 (682 - 1,333) | 2018 | Modelled | IHME |
| 948 (672 - 1,301) | 2017 | Modelled | IHME |
| 917 (655 - 1,249) | 2016 | Modelled | IHME |
| 882 (636 - 1,199) | 2015 | Modelled | IHME |
| 859 (621 - 1,148) | 2014 | Modelled | IHME |
| 841 (620 - 1,113) | 2013 | Modelled | IHME |
| 826 (617 - 1,075) | 2012 | Modelled | IHME |
| 813 (607 - 1,046) | 2011 | Modelled | IHME |
| 794 (593 - 1,022) | 2010 | Modelled | IHME |
| 762 (572 - 977) | 2009 | Modelled | IHME |
| 729 (552 - 934) | 2008 | Modelled | IHME |
| 704 (534 - 895) | 2007 | Modelled | IHME |
| 680 (520 - 866) | 2006 | Modelled | IHME |
| 654 (500 - 841) | 2005 | Modelled | IHME |
| 635 (488 - 810) | 2004 | Modelled | IHME |
| 625 (479 - 802) | 2003 | Modelled | IHME |
| 616 (476 - 789) | 2002 | Modelled | IHME |
| 607 (468 - 778) | 2001 | Modelled | IHME |
| 587 (456 - 745) | 2000 | Modelled | IHME |
| 574 (445 - 721) | 1999 | Modelled | IHME |
| 571 (447 - 713) | 1998 | Modelled | IHME |
| 571 (450 - 716) | 1997 | Modelled | IHME |
| 572 (453 - 715) | 1996 | Modelled | IHME |
| 563 (445 - 707) | 1995 | Modelled | IHME |
| 552 (437 - 688) | 1994 | Modelled | IHME |
| 547 (432 - 681) | 1993 | Modelled | IHME |
| 536 (423 - 665) | 1992 | Modelled | IHME |
| 527 (418 - 656) | 1991 | Modelled | IHME |
| 515 (403 - 647) | 1990 | Modelled | IHME |
| 1,363 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 30 (22 - 39) | 2019 | Modelled | IHME |
| 30 (23 - 40) | 2018 | Modelled | IHME |
| 30 (23 - 39) | 2017 | Modelled | IHME |
| 30 (23 - 39) | 2016 | Modelled | IHME |
| 30 (23 - 39) | 2015 | Modelled | IHME |
| 31 (23 - 39) | 2014 | Modelled | IHME |
| 31 (23 - 39) | 2013 | Modelled | IHME |
| 31 (23 - 39) | 2012 | Modelled | IHME |
| 31 (24 - 39) | 2011 | Modelled | IHME |
| 31 (24 - 39) | 2010 | Modelled | IHME |
| 31 (24 - 39) | 2009 | Modelled | IHME |
| 31 (24 - 40) | 2008 | Modelled | IHME |
| 31 (24 - 40) | 2007 | Modelled | IHME |
| 31 (24 - 40) | 2006 | Modelled | IHME |
| 32 (24 - 40) | 2005 | Modelled | IHME |
| 32 (24 - 41) | 2004 | Modelled | IHME |
| 33 (25 - 42) | 2003 | Modelled | IHME |
| 33 (25 - 43) | 2002 | Modelled | IHME |
| 34 (26 - 44) | 2001 | Modelled | IHME |
| 35 (26 - 44) | 2000 | Modelled | IHME |
| 35 (27 - 45) | 1999 | Modelled | IHME |
| 35 (27 - 45) | 1998 | Modelled | IHME |
| 35 (27 - 45) | 1997 | Modelled | IHME |
| 35 (27 - 45) | 1996 | Modelled | IHME |
| 35 (27 - 45) | 1995 | Modelled | IHME |
| 35 (27 - 45) | 1994 | Modelled | IHME |
| 35 (27 - 45) | 1993 | Modelled | IHME |
| 35 (26 - 44) | 1992 | Modelled | IHME |
| 34 (26 - 44) | 1991 | Modelled | IHME |
| 34 (25 - 44) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 98 | 2018 | Survey/reported | WHO/UNICEF |
| 98 | 2017 | Survey/reported | WHO/UNICEF |
| 98 | 2016 | Survey/reported | WHO/UNICEF |
| 97 | 2015 | Survey/reported | WHO/UNICEF |
| 97 | 2014 | Survey/reported | WHO/UNICEF |
| 97 | 2013 | Survey/reported | WHO/UNICEF |
| 97 | 2012 | Survey/reported | WHO/UNICEF |
| 96 | 2011 | Survey/reported | WHO/UNICEF |
| 95 | 2010 | Survey/reported | WHO/UNICEF |
| 98 | 2009 | Survey/reported | WHO/UNICEF |
| 94 | 2008 | Survey/reported | WHO/UNICEF |
| 97 | 2007 | Survey/reported | WHO/UNICEF |
| 98 | 2006 | Survey/reported | WHO/UNICEF |
| 89 | 2005 | Survey/reported | WHO/UNICEF |
| 98 | 2004 | Survey/reported | WHO/UNICEF |
| 99 | 2003 | Survey/reported | WHO/UNICEF |
| 98 | 2002 | Survey/reported | WHO/UNICEF |
| 98 | 2001 | Survey/reported | WHO/UNICEF |
| 96 | 2000 | Survey/reported | WHO/UNICEF |
| 98 | 2019 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 99 | 2018 | Survey/reported | WHO/UNICEF |
| 99 | 2017 | Survey/reported | WHO/UNICEF |
| 99 | 2016 | Survey/reported | WHO/UNICEF |
| 99 | 2015 | Survey/reported | WHO/UNICEF |
| 99 | 2014 | Survey/reported | WHO/UNICEF |
| 98 | 2013 | Survey/reported | WHO/UNICEF |
| 99 | 2012 | Survey/reported | WHO/UNICEF |
| 99 | 2011 | Survey/reported | WHO/UNICEF |
| 96 | 2010 | Survey/reported | WHO/UNICEF |
| 97 | 2009 | Survey/reported | WHO/UNICEF |
| 96 | 2008 | Survey/reported | WHO/UNICEF |
| 98 | 2007 | Survey/reported | WHO/UNICEF |
| 98 | 2006 | Survey/reported | WHO/UNICEF |
| 98 | 2005 | Survey/reported | WHO/UNICEF |
| 98 | 2004 | Survey/reported | WHO/UNICEF |
| 98 | 2003 | Survey/reported | WHO/UNICEF |
| 98 | 2002 | Survey/reported | WHO/UNICEF |
| 95 | 2001 | Survey/reported | WHO/UNICEF |
| 93 | 2000 | Survey/reported | WHO/UNICEF |
| 92 | 1999 | Survey/reported | WHO/UNICEF |
| 91 | 1998 | Survey/reported | WHO/UNICEF |
| 88 | 1997 | Survey/reported | WHO/UNICEF |
| 93 | 1996 | Survey/reported | WHO/UNICEF |
| 88 | 1995 | Survey/reported | WHO/UNICEF |
| 67 | 1994 | Survey/reported | WHO/UNICEF |
| 69 | 1993 | Survey/reported | WHO/UNICEF |
| 47 | 1992 | Survey/reported | WHO/UNICEF |
| 18 | 1991 | Survey/reported | WHO/UNICEF |
| 98 | 2019 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 9.34 (7.16 - 12.08) | 2019 | Modelled | IHME |
| 9.4 (7.25 - 12.30) | 2018 | Modelled | IHME |
| 9.49 (7.26 - 12.61) | 2017 | Modelled | IHME |
| 9.67 (7.43 - 12.78) | 2016 | Modelled | IHME |
| 9.88 (7.34 - 13.19) | 2015 | Modelled | IHME |
| 10.11 (7.57 - 13.37) | 2014 | Modelled | IHME |
| 10.4 (7.81 - 13.61) | 2013 | Modelled | IHME |
| 10.67 (8.11 - 13.80) | 2012 | Modelled | IHME |
| 10.88 (8.28 - 13.95) | 2011 | Modelled | IHME |
| 10.96 (8.33 - 14.12) | 2010 | Modelled | IHME |
| 10.84 (8.26 - 13.85) | 2009 | Modelled | IHME |
| 10.53 (8.07 - 13.33) | 2008 | Modelled | IHME |
| 10.15 (7.82 - 12.71) | 2007 | Modelled | IHME |
| 9.79 (7.55 - 12.20) | 2006 | Modelled | IHME |
| 9.58 (7.39 - 11.97) | 2005 | Modelled | IHME |
| 9.47 (7.42 - 11.73) | 2004 | Modelled | IHME |
| 9.37 (7.41 - 11.49) | 2003 | Modelled | IHME |
| 9.29 (7.34 - 11.41) | 2002 | Modelled | IHME |
| 9.23 (7.37 - 11.33) | 2001 | Modelled | IHME |
| 9.21 (7.35 - 11.34) | 2000 | Modelled | IHME |
| 9.2 (7.37 - 11.33) | 1999 | Modelled | IHME |
| 9.2 (7.40 - 11.39) | 1998 | Modelled | IHME |
| 9.2 (7.39 - 11.43) | 1997 | Modelled | IHME |
| 9.2 (7.37 - 11.47) | 1996 | Modelled | IHME |
| 9.2 (7.31 - 11.50) | 1995 | Modelled | IHME |
| 9.19 (7.33 - 11.51) | 1994 | Modelled | IHME |
| 9.18 (7.35 - 11.50) | 1993 | Modelled | IHME |
| 9.16 (7.29 - 11.45) | 1992 | Modelled | IHME |
| 9.15 (7.29 - 11.41) | 1991 | Modelled | IHME |
| 9.13 (7.26 - 11.42) | 1990 | Modelled | IHME |
| 6.4 (4.30 - 7.90) | 2015 | Modelled | Blach et al, 2017 |
| 7.5 (6.10 - 10.90) | 2014 | Modelled | Gower et al, 2014 |
| 6.4 (4.30 - 7.90) | 2015 | Modelled | Blach et al, 2017 |
| 7.5 (6.10 - 10.90) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 10.8 (8.70 - 15.60) | 2014 | Modelled | Gower et al, 2014 |
| 10.8 (8.70 - 15.60) | 2014 | Modelled | Gower et al, 2014 |
| 10.8 (8.70 - 15.60) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 196,661 (156,414 - 245,865) | 1990 | Modelled | IHME |
| 200,685 (159,803 - 250,179) | 1991 | Modelled | IHME |
| 204,428 (162,520 - 255,461) | 1992 | Modelled | IHME |
| 207,814 (166,437 - 260,338) | 1993 | Modelled | IHME |
| 210,869 (168,275 - 264,095) | 1994 | Modelled | IHME |
| 213,617 (169,862 - 267,144) | 1995 | Modelled | IHME |
| 216,132 (173,090 - 269,592) | 1996 | Modelled | IHME |
| 218,484 (175,426 - 271,354) | 1997 | Modelled | IHME |
| 220,812 (177,491 - 273,248) | 1998 | Modelled | IHME |
| 223,127 (178,578 - 274,794) | 1999 | Modelled | IHME |
| 225,571 (180,087 - 277,675) | 2000 | Modelled | IHME |
| 228,496 (182,346 - 280,505) | 2001 | Modelled | IHME |
| 232,367 (183,587 - 285,389) | 2002 | Modelled | IHME |
| 237,054 (187,579 - 290,784) | 2003 | Modelled | IHME |
| 242,512 (189,975 - 300,447) | 2004 | Modelled | IHME |
| 248,611 (191,782 - 310,738) | 2005 | Modelled | IHME |
| 257,987 (198,837 - 321,473) | 2006 | Modelled | IHME |
| 271,610 (209,275 - 340,291) | 2007 | Modelled | IHME |
| 286,861 (219,913 - 363,083) | 2008 | Modelled | IHME |
| 300,823 (229,337 - 384,374) | 2009 | Modelled | IHME |
| 310,393 (235,739 - 399,832) | 2010 | Modelled | IHME |
| 314,389 (239,350 - 402,943) | 2011 | Modelled | IHME |
| 314,890 (239,291 - 407,295) | 2012 | Modelled | IHME |
| 313,349 (235,286 - 410,093) | 2013 | Modelled | IHME |
| 311,386 (233,147 - 411,857) | 2014 | Modelled | IHME |
| 310,716 (230,860 - 414,882) | 2015 | Modelled | IHME |
| 310,171 (238,318 - 410,167) | 2016 | Modelled | IHME |
| 310,523 (237,505 - 412,587) | 2017 | Modelled | IHME |
| 313,093 (241,351 - 409,580) | 2018 | Modelled | IHME |
| 316,502 (242,400 - 409,223) | 2019 | Modelled | IHME |
| 194,000 (131,000 - 237,000) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 30.8 (22.50 - 41) | 2019 | Modelled | IHME |
| 30.2 (22.20 - 39.80) | 2018 | Modelled | IHME |
| 29.7 (21.90 - 39.30) | 2017 | Modelled | IHME |
| 29.5 (21.70 - 39.20) | 2016 | Modelled | IHME |
| 28.8 (21.50 - 38.20) | 2015 | Modelled | IHME |
| 28.7 (21.80 - 37.70) | 2014 | Modelled | IHME |
| 28.8 (21.90 - 37.60) | 2013 | Modelled | IHME |
| 29 (22 - 37.60) | 2012 | Modelled | IHME |
| 29.4 (22.10 - 37.90) | 2011 | Modelled | IHME |
| 29.3 (22.20 - 37.50) | 2010 | Modelled | IHME |
| 28.7 (21.90 - 36.50) | 2009 | Modelled | IHME |
| 28 (21.30 - 35.50) | 2008 | Modelled | IHME |
| 27.5 (21.10 - 34.70) | 2007 | Modelled | IHME |
| 26.9 (20.50 - 34.30) | 2006 | Modelled | IHME |
| 25.9 (19.60 - 33.20) | 2005 | Modelled | IHME |
| 24.7 (18.80 - 31.70) | 2004 | Modelled | IHME |
| 23.4 (17.70 - 30.10) | 2003 | Modelled | IHME |
| 21.8 (16.30 - 28.30) | 2002 | Modelled | IHME |
| 20.4 (15.20 - 26.80) | 2001 | Modelled | IHME |
| 18.9 (14 - 24.70) | 2000 | Modelled | IHME |
| 17.9 (13.30 - 23.50) | 1999 | Modelled | IHME |
| 17.4 (13 - 22.70) | 1998 | Modelled | IHME |
| 17.1 (13 - 22.40) | 1997 | Modelled | IHME |
| 17.1 (13 - 22.50) | 1996 | Modelled | IHME |
| 16.9 (12.80 - 22) | 1995 | Modelled | IHME |
| 16.7 (12.80 - 21.60) | 1994 | Modelled | IHME |
| 16.9 (12.90 - 21.90) | 1993 | Modelled | IHME |
| 17.1 (13.20 - 21.90) | 1992 | Modelled | IHME |
| 17.3 (13.30 - 22.10) | 1991 | Modelled | IHME |
| 17.4 (13.10 - 22.20) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,044 (763 - 1,389) | 2019 | Modelled | IHME |
| 1,005 (740 - 1,326) | 2018 | Modelled | IHME |
| 973 (715 - 1,284) | 2017 | Modelled | IHME |
| 945 (698 - 1,258) | 2016 | Modelled | IHME |
| 905 (677 - 1,202) | 2015 | Modelled | IHME |
| 882 (670 - 1,161) | 2014 | Modelled | IHME |
| 870 (660 - 1,133) | 2013 | Modelled | IHME |
| 857 (649 - 1,110) | 2012 | Modelled | IHME |
| 848 (638 - 1,094) | 2011 | Modelled | IHME |
| 830 (627 - 1,061) | 2010 | Modelled | IHME |
| 796 (607 - 1,013) | 2009 | Modelled | IHME |
| 762 (580 - 968) | 2008 | Modelled | IHME |
| 735 (566 - 929) | 2007 | Modelled | IHME |
| 710 (540 - 903) | 2006 | Modelled | IHME |
| 674 (510 - 862) | 2005 | Modelled | IHME |
| 634 (481 - 811) | 2004 | Modelled | IHME |
| 593 (449 - 762) | 2003 | Modelled | IHME |
| 547 (407 - 708) | 2002 | Modelled | IHME |
| 505 (376 - 664) | 2001 | Modelled | IHME |
| 462 (343 - 605) | 2000 | Modelled | IHME |
| 433 (323 - 569) | 1999 | Modelled | IHME |
| 417 (313 - 546) | 1998 | Modelled | IHME |
| 407 (308 - 532) | 1997 | Modelled | IHME |
| 402 (304 - 528) | 1996 | Modelled | IHME |
| 392 (298 - 511) | 1995 | Modelled | IHME |
| 384 (293 - 496) | 1994 | Modelled | IHME |
| 382 (292 - 495) | 1993 | Modelled | IHME |
| 380 (293 - 488) | 1992 | Modelled | IHME |
| 379 (291 - 485) | 1991 | Modelled | IHME |
| 374 (283 - 477) | 1990 | Modelled | IHME |
| 603 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 30 (21 - 38) | 2019 | Modelled | IHME |
| 30 (21 - 38) | 2018 | Modelled | IHME |
| 30 (21 - 38) | 2017 | Modelled | IHME |
| 30 (22 - 38) | 2016 | Modelled | IHME |
| 30 (22 - 38) | 2015 | Modelled | IHME |
| 30 (22 - 38) | 2014 | Modelled | IHME |
| 30 (22 - 39) | 2013 | Modelled | IHME |
| 30 (22 - 39) | 2012 | Modelled | IHME |
| 31 (23 - 39) | 2011 | Modelled | IHME |
| 31 (23 - 39) | 2010 | Modelled | IHME |
| 31 (23 - 39) | 2009 | Modelled | IHME |
| 31 (23 - 40) | 2008 | Modelled | IHME |
| 31 (23 - 40) | 2007 | Modelled | IHME |
| 31 (23 - 40) | 2006 | Modelled | IHME |
| 31 (23 - 40) | 2005 | Modelled | IHME |
| 31 (23 - 40) | 2004 | Modelled | IHME |
| 31 (22 - 40) | 2003 | Modelled | IHME |
| 30 (22 - 39) | 2002 | Modelled | IHME |
| 30 (22 - 39) | 2001 | Modelled | IHME |
| 30 (21 - 38) | 2000 | Modelled | IHME |
| 29 (21 - 38) | 1999 | Modelled | IHME |
| 29 (21 - 38) | 1998 | Modelled | IHME |
| 29 (21 - 38) | 1997 | Modelled | IHME |
| 29 (21 - 38) | 1996 | Modelled | IHME |
| 29 (21 - 39) | 1995 | Modelled | IHME |
| 30 (21 - 39) | 1994 | Modelled | IHME |
| 30 (21 - 39) | 1993 | Modelled | IHME |
| 30 (22 - 40) | 1992 | Modelled | IHME |
| 31 (22 - 40) | 1991 | Modelled | IHME |
| 31 (22 - 41) | 1990 | Modelled | IHME |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2020
Prevalence (national)
Modelled
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.29
(%)
2019, latest modelled
(0.20 - 0.36(%))
IHME
Prevalence PWID
No data available
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
